Enimmune corporation
6564
Rank in Stocks
#24530
Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused... Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.
Share Price
$0.4450731
Last synced: 2026-11-10
Market Cap
$32.25M
Change (1 day)
-2.34%
Change (1 year)
-32.85%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Enimmune corporation (6564)
Category
Healthcare
EPS for Enimmune corporation (6564)
EPS as of June 2026 TTM: $-0.05
According to Enimmune corporation's latest financial reports, its current EPS (TTM) is $-0.05. At the end of 2025 the company had an EPS of $-0.07, equal to its 2024 EPS of $-0.07.
EPS history for Enimmune corporation from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.05 | -25.86% |
| 2025 | $-0.07 | 8.36% |
| 2024 | $-0.07 | -39.53% |
| 2023 | $-0.11 | -12.41% |
| 2022 | $-0.13 | 343.86% |
| 2021 | $-0.03 | -42.42% |
| 2020 | $-0.05 | 15.65% |
| 2019 | $-0.04 | -44.77% |
| 2018 | $-0.08 | 167.24% |
| 2017 | $-0.03 | -42.69% |
| 2016 | $-0.05 | 54.27% |
| 2015 | $-0.03 | 389.55% |
| 2014 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -30,273.41% |
US
|
|
| $-7.07 | 13,522.35% |
US
|
|
| $-5.29 | 10,092.68% |
AU
|
|
| $12.88 | -24,917.15% |
BE
|
|
| $21.56 | -41,641.43% |
NL
|
Questions about Enimmune corporation's earnings per share (EPS)
What is Enimmune corporation's earnings per share (EPS)?
Enimmune corporation's earnings per share (EPS) over the last twelve months is $-0.05, as of Jun 2026.
What was Enimmune corporation's earnings per share (EPS) in 2025?
In 2025, Enimmune corporation's earnings per share (EPS) was $-0.07, compared with $-0.07 in 2024.
How has Enimmune corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Enimmune corporation's earnings per share (EPS) was highest in 2021 ($-0.03) and lowest in 2022 ($-0.13).
How does Enimmune corporation's earnings per share (EPS) compare with similar companies?
Enimmune corporation's earnings per share (EPS) ($-0.05) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.